Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anileridine is a synthetic opioid analgesic of the piperidine class developed by Merck & Co. in the 1950s for the treatment of moderate to severe pain. It acts primarily as a mu-type opioid receptor agonist in the central nervous system (CNS), producing analgesia by mimicking endogenous opioids and inhibiting nociceptive neurotransmitter release. Anileridine was used both as a pain reliever and as an adjunct to anesthesia but is no longer manufactured in the US or Canada. Its pharmacological effects are similar to those of morphine and meperidine but with some differences in side effect profile and duration of respiratory depression[2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anileridine.